Menghis Bairu, is a physician, entrepreneur, coach, business executive, editor, author, and philanthropist. He has 30 plus years of international experience in the biotechnology, pharmaceutical, drug delivery and device, global health, and non-profit arenas.

Dr. Bairu is founder, chairman, and CEO of Proxenia Venture Partners, which provides capital, experienced management, and access to a global networks of experts to companies in early and late stage clinical development in biotechnology that address global challenges and improve patient lives. Most recently, he served as Executive Chairman of Treos Bio, a start-up company that uses computational biology to develop precision cancer immunotherapies tailored to patients' genetics. In addition, he is Founder and Chairman Emeritus of Serenus Biotherapeutics, an emerging market focused specialty biopharmaceutical company. In that role he raised up to $43 million in series A funding.

Dr. Bairu concurrently served as Executive Vice President, Chief Medical Officer, Head of Global Development for Elan and President/CEO of Speranza Therapeutics. As EVP and CMO, Dr. Bairu was member of the Elan’s Operating Committee. He successfully led corporate R&D due diligence processes that resulted in a transaction with J&J at a value of approximately $1.5 billion. In 2013, he also led corporate R&D due diligence resulting in the sale of Elan to Perrigo for $8.6 billion.

Read more: https://advanceprotein.com/corporate-strategic-advisor-of-advance-international/